Since P53 and MDM2 were not deregulated in PIA samples, and both markers have instead been described as altered in PC [16,38], P53 downregulation and MDM2 overexpression may occur only in the advanced stage of prostatic carcinogenesis, after malignant transformation. The gene discussed is MDM2; the disease is medical procedure.